Stockreport

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Corporation - Class A  (IMRX) 
PDF - Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - [Read more]